Grass City 20% OFF

Stock Research Monitor: AMAG, AMGN, and ARNA

LONDON, UK / ACCESSWIRE / June 13, 2018 / If you want a free Stock Review on ARQL sign up now at . features the Biotechnology sector, which is one of the hardest sectors to invest in. Biotech investing is for the robust investor seeking high risk/reward on a roller coaster. It is not for the risk averse. In today’s pre-market research, four stocks are presented for scanning: AMAG Pharmaceuticals Inc. (NASDAQ: AMAG ), Amgen Inc. (NASDAQ: AMGN ), Arena Pharmaceuticals Inc. (NASDAQ: ARNA ), and ArQule Inc. (NASDAQ: ARQL ). All you have to do is sign up today for this free limited time offer by clicking the link below.

AMAG Pharmaceuticals

Shares in Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc. saw a slight decline of 0.62%, ending Tuesday’s trading session at $23.95. The stock recorded a trading volume of 606,545 shares. The Company’s shares have gained 19.15% over the last three months and 36.86% over the past year. The stock is trading 8.12% and 34.23% above its 50-day and 200-day moving averages, respectively. Moreover, shares of AMAG Pharma, which manufactures, develops, and commercializes therapeutics for maternal and women’s health, anemia management, and cancer supportive care in the US, have a Relative Strength Index (RSI) of 52.71.

On May 21st, 2018, research firm Leerink Partners resumed its ‘Market Perform’ rating on the Company’s stock.

On June 04th, 2018, AMAG Pharma announced that the US FDA has accepted the Company’s NDA for bremelanotide, a first-in-class melanocortin 4 receptor agonist designed for the treatment of hypoactive sexual desire disorder in premenopausal women. The Prescription Drug User Fee Act date for completion of FDA review of the bremelanotide NDA is March 23rd, 2019. Get the full research report on AMAG for free by clicking below at:


Thousand Oaks, California headquartered Amgen Inc.’s stock rose slightly by 0.25%, closing the day at $185.07 with a total trading volume of 2.01 million shares. The Company’s shares have advanced 6.43% in the past month and 12.25% over the past year. The stock is trading 5.97% and 3.35% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Amgen, which discovers, develops, manufactures, and delivers human therapeutics worldwide, have an RSI of 65.09.

On June 11th, 2018, Amgen announced that the U.S. Food and Drug Administration has approved the supplemental New Drug Application to add the positive overall survival data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (carfilzomib). Data added to the label showed that KYPROLIS, lenalidomide and dexamethasone significantly reduced the risk of death by 21% and extended overall survival by 7.9 months versus lenalidomide and dexamethasone alone in patients with relapsed or refractory multiple myeloma. Gain free access to the research report on AMGN at:

Arena Pharmaceuticals

On Tuesday, shares in San Diego, California-based Arena Pharmaceuticals Inc. recorded a trading volume of 552,617 shares. The stock ended the day 1.22% higher at $48.94. The Company’s shares have advanced 8.78% in the past month, 24.59% in the previous three months, and 252.09% over the past year. The stock is trading above its 50-day and 200-day moving averages by 16.34% and 41.97%, respectively. Furthermore, shares of Arena Pharma, which focuses on developing novel small molecule drugs for various therapeutic areas in the US and Switzerland, have an RSI of 69.06.

On May 31st, 2018, research firm RBC Capital Markets initiated an ‘Outperform’ rating on the Company’s stock, with a target price of $65 per share. Signing up today on Wall St. Equities will give you access to the latest report on ARNA at:


Burlington, Massachusetts headquartered ArQule Inc.’s stock declined 1.89%, finishing yesterday’s session at $5.18. A total volume of 2.40 million shares was traded, which was above their three months average volume of 1.43 million shares. The Company’s shares have surged 87.68% in the last month, 183.06% in the previous three months, and 362.50% over the past year. The stock is trading above its 50-day and 200-day moving averages by 49.50% and 159.04%, respectively. Additionally, shares of ArQule, which researches and develops therapeutics for the treatment of cancer and rare diseases in the US, have an RSI of 64.80.

On June 07th, 2018, ArQule announced that clinical data from the Company-sponsored ARQ 531-101 Phase-1 dose escalation study in subjects with relapsed or refractory hematologic malignancies will be presented on June 15th, 2018 from 17:30 CET to 19:00 CET at the EHA Congress in Stockholm, Sweden. ARQ 531 is an orally bioavailable, potent, and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase. Register now for today’s free coverage on ARQL at:

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email . Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:


Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

Stock Symbols